Why the study?
Several recent RCTs have investigated DOACs for malignancy-associated VTE, warranting a meta-analysis combining all RCT data to evaluate the risks of recurrent VTE and bleeding compared with LMWH.
Do direct oral anticoagulants (DOAC) reduce recurrent VTE compared to low-molecular-weight heparin (LMWH) in patients with malignancy-associated VTE?
Population
2907 patients with malignancy-associated VTE across four RCTs
Comparison
DOACs vs LMWH
Design
Systematic review and direct and indirect network meta-analysis
Authors
Loading...
Supports DOACs over LMWH for cancer-associated VTE; reinforces RCT data while highlighting bleeding trade-offs.
Do direct oral anticoagulants (DOAC) reduce recurrent VTE compared to low-molecular-weight heparin (LMWH) in patients with malignancy-associated VTE?
DOACs are effective for treating malignancy-associated VTE, reducing recurrent VTE compared to LMWH, though they may increase the risk of clinically relevant non-major bleeding.
Samaranayake et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: